Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company’s Founder and CEO, Dr. Robert Hariri, M.D., Ph.D., will present on the promise of cellular therapy to improve longevity at this year’s ABUNDANCE Summit on March 21, 2024.

Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases. Dr. Hariri has led the effort to harness the unique biology of placental-derived cells in a range of clinical indications, including cancer, autoimmune and degenerative diseases. Dr. Hariri will also discuss how cellular therapeutics derived from newborn cells from the placenta can shift the biology of aging with the potential to extend and preserve human performance with age.

“Celularity continues to invest in the research behind cellular immunotherapy, which looks at how stem and immune cells can be used to regenerate failing organs or damaged tissues that occur with various age-related degenerative disorders and diseases,” said Dr. Hariri. “We pioneered the use of cells derived from the postpartum placenta, including stem and immune cells, and today, Celularity’s Lifebank newborn cell banking division is the world’s largest repository of autologous placental-derived cells. We believe that scientists have only scratched the surface in terms of understanding cellular immunotherapy’s full potential for improving longevity.”

“The field of cellular medicine is uniquely poised to revolutionize medicine as a whole through augmenting our biology, immunity, and longevity,” added Dr. Peter Diamandis, M.D., Abundance360 and Singularity University Founder. “Dr. Hariri has been a pioneer in cellular and regenerative medicine and his seminal research, some of it going back to his graduate work at Cornell, connected the biology of aging to the biology of degenerative diseases, even cancer. At Celularity, Bob is making significant progress in harnessing the unique power of cellular medicine derived from the post-partum placenta, a technology he discovered, to potentially delay or even reverse some of the biological processes that contribute to aging. This work puts Dr. Hariri at the forefront of the longevity movement, with his finger on the pulse of the ever-changing landscape.”

The ABUNDANCE Summit will occur in Los Angeles, Calif., from March 17 through 21, 2024.

About Celularity Celularity Inc. (NASDAQ: CELU) is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic, cryopreserved, placental-derived cell therapies, including therapeutic programs using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells) and genetically modified and unmodified natural killer (NK) cells. These therapeutic programs target indications in autoimmune, infectious, and degenerative diseases. In addition, Celularity develops, manufactures, and commercializes innovative biomaterial products also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

Forward-Looking StatementsThis press release includes “forward-looking statements” within the meaning of U.S. The Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “promise” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include statements regarding the ability of Celularity to develop transformative therapies for patients with neurological disorders using our technology platform employing placental-derived cells, biological materials, and byproducts; Celularity’s ability to advance our pipeline to address aging related healthcare challenges, including cancer; as well as the promise of cellular and regenerative therapy in treating age-related cognitive decline; and the broad potential of Celularity’s cell therapy portfolio, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: the inherent risks in biotechnological development, including with respect to the development of novel cellular therapies, and the clinical trial and regulatory approval process; and risks associated with Celularity’s current liquidity, as well as developments relating to Celularity’s competitors and industry, along with those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2023, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Investor Contact: Carlos RamirezSenior Vice President, Celularity [e-mail]

Media Contacts: Caitlin Kasunich / Ali NagyKCSA Strategic [e-mail] / [e-mail]